Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Post-Microneedling Skin Care

PreclinicalSmall molecule

EEnglewood Hospital and Medical Center

Post-Microneedling Skin Care is one of 2 small molecule programs targeting Scar. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

ScarCompleted

ScarPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Scar

#DrugCompanyPhaseTrials

Post-Microneedling Skin Care

EEnglewood Hospital and Medical Center

Icariin

UUniversity of Texas Southwestern Medical Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Scar1 trial

Microneedling Plus the Universal Peel For Acne Scarring

Completed·EEnglewood Hospital and Medical Center·N/A·NCT02174393·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Post-Microneedling Skin Care. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Post-Microneedling Skin Care compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Post-Microneedling Skin Care. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Englewood Hospital and Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEnglewood Hospital and Medical Center

Related News